TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia

Phase 3

Completed

• Conditions: Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hemorrhage
• Interventions: Drug: Tranexamic acid (TXA).; Drug: Placebo

• Registration Number: NCT03136445
• Lead Sponsor: NHS Blood and Transplant

Brief Summary

The purpose of this study is to test whether giving tranexamic acid to patients receiving treatment for blood cancers reduces the risk of bleeding or death, and the need for platelet transfusions. Patients will be randomised to receive tranexamic acid (given intravenously through a drip, or orally) or a placebo.

Detailed Description

Patients with cancers of the blood often develop low blood cell counts either as a consequence of the disease or the treatment by chemotherapy or stem cell transplantation. Platelet transfusions are commonly given to raise any low platelet count and reduce the risk of clinical bleeding (prophylaxis) or stop active bleeding (therapy). But recent studies have indicated that many patients continue to experience bleeding, despite the use of platelet transfusions. Tranexamic acid is a type of drug that is called an antifibrinolytic. These drugs act to reduce the breakdown of clots formed in response to bleeding. These drugs have been used widely in both elective and emergency surgery and have been shown to decrease blood loss and the use of red cell transfusions. The purpose of this study is to test whether giving tranexamic acid to patients receiving treatment for blood cancers reduces the risk of bleeding or death, and the need for platelet transfusions. Patients will be randomised to receive tranexamic acid (given intravenously through a drip, or orally) or a placebo. The investigators will measure the rates of bleeding daily using a short structured assessment of bleeding and will record the number of transfusions given to patients.

Study Timeline

• Study Start: 2015-06
• Study First Submitted: 2017-02-21
• Study First Submitted QC: 2017-04-26
• Study First Posted: 2017-05-02
• Primary Completion: 2022-02-18
• Study Completion: 2022-06-18
• Status Verified: 2023-11
• Last Update Submitted: 2024-12-09
• Last Update Posted: 2024-12-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 616

Inclusion Criteria

Patients are eligible for this trial if:

1. Aged ≥18 years of age
2. Confirmed diagnosis of a haematological malignancy
3. Undergoing chemotherapy, or chemotherapy is planned, or haematopoietic stem cell transplantation
4. Anticipated to have a hypoproliferative thrombocytopenia resulting in a platelet count of ≤10x10⁹/L for ≥ 5 days
5. Able to comply with treatment and monitoring

Exclusion Criteria

A patient will not be eligible for this trial if he/she fulfils one or more of the following criteria:

1. Patients with a past history or current diagnosis of arterial or venous thromboembolic disease including myocardial infarction, peripheral vascular disease and retinal arterial or venous thrombosis.

2. Diagnosis of acute promyelocytic leukaemia (APML) and undergoing induction chemotherapy

3. Patients with a diagnosis/previous history of veno-occlusive disease (also called sinusoidal obstruction syndrome)

4. Patients with known inherited or acquired prothrombotic disorders e.g.

   1. Lupus anticoagulant
   2. Positive antiphospholipids

5. Patients receiving any pro-coagulant agents (e.g. DDAVP, recombinant Factor VIIa or Prothrombin Complex Concentrates (PCC) within 48 hours of enrolment, or with known hypercoagulable state

6. Patients receiving L-asparaginase as part of their current cycle of treatment

7. History of immune thrombocytopenia (ITP), thrombotic thrombocytopenic purpura (TTP) or haemolytic uraemic syndrome (HUS)

8. Patients with overt disseminated intravascular coagulation (DIC) (See Appendix 3 in the protocol for definition)

9. Patients requiring a platelet transfusion threshold >10x10/⁹L at time of randomisation. (This refers to patients who require their platelet count to be maintained at a certain specified level on an ongoing basis, and excludes a transient rise in the threshold due to sepsis.)

10. Patients with a known inherited or acquired bleeding disorder e.g.

    1. Acquired storage pool deficiency
    2. Paraproteinaemia with platelet inhibition

11. Patients receiving anticoagulant therapy or anti-platelet therapy

12. Patients with visible haematuria at time of randomisation

13. Patients with anuria (defined as urine output < 10 mls/hr over 24 hours).

14. Patients with severe renal impairment (eGFR ≤30 ml/min/1.73m²)

15. Patients with a previous history of epilepsy, convulsions, fits or seizures

16. Patients who are pregnant or breast-feeding

17. Allergic to tranexamic acid.

18. Patients enrolled in other trials involving platelet transfusions, anti-fibrinolytics, platelet growth factors or other pro-coagulant agents.

19. Patients previously randomised into this trial at any stage of their treatment.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Intervention Arm	Tranexamic acid (TXA).	Tranexamic acid (TXA). Dose schedule TXA 1g every eight hours IV or 1.5g every eight hours PO.
Control Arm	Placebo	Placebo (saline) if administration is IV. Placebo tablet matched for appearance to TXA if oral.

Primary Outcome Measures

Name	Time	Method
The proportion of patients who die or have bleeding of WHO grade 2 or above by WHO criteria during the first 30 days from the first dose of trial treatment, or planned first dose for those participants who do not receive treatment.	The first 30 days from first dose of trial treatment	The proportion of patients who die or have bleeding of WHO grade 2 or above by WHO criteria during the first 30 days from the first dose of trial treatment, or planned first dose for those participants who do not receive treatment.; A time-to-event analysis will be used to determine this proportion to ensure that all patients are included in the primary outcome analysis, not just those who are followed up for the full 30 days. Any patients lost to follow-up will be included in the analysis and censored at the time that they were lost.

Secondary Outcome Measures

Name	Time	Method
Number of platelet transfusions per patient up to study day 30.	The first 30 days from first dose of trial treatment.	Measured by number of recorded platelet transfusions per patient.
Proportion of patients surviving at least 30 days without a red cell transfusion.	The first 30 days from first dose of trial treatment.	Measured by calculating the number of patients surviving at least 30 days without a red cell transfusion.
Death due to thrombosis during the first 120 days after the first dose of trial treatment is administered.	Up to and including 120 days from the first administration of IMP.	Measured by calculating number of deaths due to thrombosis during the first 120 days after Treatment Day 1 i.e the first day that the IMP is administered.
Time to first episode of bleeding of WHO grade 2 or greater up to study day 30.	The first 30 days from first dose of trial treatment.	Bleeding assessed using WHO bleeding criteria.
Death due to bleeding during the first 30 days after the first dose of trial treatment is administered.	Up to and including 30 days from the first administration of IMP.	Measured by calculating number of deaths due to bleeding during the first 30 days
Number of serious adverse events (SAE) from first administration of trial treatment until 60 days after the first dose of trial treatment is administered.	Up to and including 60 days from the first administration of IMP.	Measured by calculating the total number of SAE's reported from first administration of IMP.
Proportion of days with bleeding (WHO grade 2 or above) up to Study Day 30.	The first 30 days from first dose of trial treatment .	Number of days where WHO grade 2 or above bleeding has been recorded bleeding using WHO bleeding criteria.
Highest grade of bleeding a patient experiences up to study day 30.	The first 30 days from first dose of trial treatment.	Measured using WHO bleeding criteria.
Number of red cell transfusions per patient up to study day 30.	The first 30 days from first dose of trial treatment.	Measured by number of recorded red cell transfusions per patient.
Proportion of patients surviving at least 30 days without a platelet transfusion.	The first 30 days from first dose of trial treatment.	Measured by calculating number of patients surviving at least 30 days without a platelet transfusion.
Number of thrombotic events from first administration of trial treatment up to and including 120 days after the first dose of trial treatment is administered, per day at risk.	Up to and including 120 days from the first administration of investigational medicinal product (IMP).	Measured by calculating number of clinically diagnosed thrombotic events from Treatment Day 1 i.e the first day that the investigational medicinal product (IMP) is administered, up to and including the next 120 days.
All-cause mortality during the first 30 days and 120 days after the first dose of trial treatment is administered. All-cause mortality during the first 30 days and 120 days after the first dose of trial treatment is administered	Up to and including 120 days from the first administration of IMP.	Measured by calculating number of deaths in first 30 days and 120 days after Treatment Day 1 i.e the first day that the IMP is administered.
Number of patients developing Veno-occlusive Disease (VOD; Sinusoidal obstructive syndrome, SOS) within 60 days of first administration of trial treatment.	Up to and including 60 days from the first administration of IMP.	Measured by calculating number of patients developing Veno-occlusive Disease (VOD; Sinusoidal obstructive syndrome, SOS) within 60 days of Treatment Day 1 i.e the first day that the IMP is administered.

Trial Locations

Locations (26)

Queen Elizabeth Hospital; 🇬🇧 Birmingham, United Kingdom

Royal Adelaide Hospital; 🇦🇺 Adelaide, Australia

Andrew Love Cancer Centre; 🇦🇺 Geelong, Australia

Royal Brisbane; 🇦🇺 Brisbane, Australia

Alfred Hospital; 🇦🇺 Melbourne, Australia

Belfast City Hospital; 🇬🇧 Belfast, United Kingdom

University Hospital Coventry; 🇬🇧 Coventry, United Kingdom

St Vincent's Hospital; 🇦🇺 Sydney, Australia

King's College Hospital; 🇬🇧 London, United Kingdom

Royal United Hospital; 🇬🇧 Bath, United Kingdom

Westmead Hospital; 🇦🇺 Westmead, Australia

Heartlands Hospital; 🇬🇧 Birmingham, United Kingdom

Royal North Shore Hospital; 🇦🇺 St Leonards, Australia

Bristol Haematology and Oncology Centre; 🇬🇧 Bristol, United Kingdom

Royal Devon and Exeter Hospital; 🇬🇧 Exeter, United Kingdom

St James's Hospital; 🇬🇧 Leeds, United Kingdom

Canberra Hospital; 🇦🇺 Canberra, Australia

Salisbury District Hospital; 🇬🇧 Salisbury, United Kingdom

Beatson West of Scotland Cancer Centre; 🇬🇧 Glasgow, United Kingdom

Lincoln County Hospital; 🇬🇧 Lincoln, United Kingdom

University College London Hospitals; 🇬🇧 London, United Kingdom

Victorian Comprehensive Cancer Centre; 🇦🇺 Melbourne, Australia

Churchill Hospital; 🇬🇧 Oxford, United Kingdom

Derriford Hospital; 🇬🇧 Plymouth, United Kingdom

Monash Health; 🇦🇺 Melbourne, Australia

Freeman Hospital; 🇬🇧 Newcastle, United Kingdom